文献速递妇科生殖医学

早期宫颈癌保留生育功能手术与标准手术:5年预期寿命差异随肿瘤大小的变化

Fertility-sparing surgery vs standard surgery for early-stage cervical cancer: difference in 5-year life expectancy by tumor size.
PubMed 文献 · Am J Obstet Gynecol · 2024-02-15

本研究基于美国国家癌症数据库2006至2018年≤45岁、I期、肿瘤≤4 cm的宫颈癌患者,比较保留生育功能手术与标准手术的5年预期寿命差异。倾向评分匹配后,两种手术的5年预期寿命相似,但肿瘤>2 cm者接受保留生育功能手术的例数很少,不能排除临床重要的生存差异。

要点

  • 在≤4 cm的I期宫颈癌年轻患者中,保留生育功能手术与标准手术的5年预期寿命相似。
  • 肿瘤越小,保留生育功能手术相关预期寿命差异的估计越精确。
  • 接受辅助放疗的概率随肿瘤增大而升高,从1 cm的5.6%升至4 cm的37%。

核心结论

  • 在诊断后5年内,≤4 cm的I期宫颈癌年轻患者接受保留生育功能手术或标准手术的生存结局相似。
  • 由于肿瘤>2 cm者接受保留生育功能手术的例数很少,不能排除该人群存在临床重要的生存差异。

研究设计与样本

  • 研究为基于美国国家癌症数据库的队列分析,纳入2006至2018年≤45岁、I期、肿瘤最大径≤4 cm、未接受术前放化疗且以保留生育功能手术或标准手术作为主要治疗的宫颈癌患者。
  • 共11,946例患者符合纳入标准,其中904例(7.6%)接受保留生育功能手术;倾向评分匹配后,897例保留生育功能手术患者与897例标准手术患者按1:1匹配。
  • 采用灵活参数模型按肿瘤大小量化两组诊断后5年内预期寿命差异(限制性平均生存时间),并在保留生育功能手术组用逻辑回归模型分析肿瘤大小与接受辅助放疗概率的关系。

主要发现

  • 无论肿瘤大小,保留生育功能手术与标准手术患者的5年预期寿命相似。
  • 1 cm肿瘤的预期寿命差异为-0.10个月(95%置信区间,-0.67至0.47),4 cm肿瘤为-0.11个月(95%置信区间,-3.79至3.57),肿瘤较小时估计更精确。
  • 接受辅助放疗的概率随肿瘤增大而升高,从1 cm肿瘤的5.6%(95%置信区间,3.9-7.9)升至4 cm肿瘤的37%(95%置信区间,24.3-51.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 由于肿瘤>2 cm者接受保留生育功能手术的例数很少,不能排除该人群存在临床重要的生存差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical cancer incidence among premenopausal women is rising, and fertility-sparing surgery serves as an important option for this young population. There is a lack of evidence on what tumor size cutoff should be used to define candidacy for fertility-sparing surgery. OBJECTIVE: We sought to describe how the association between fertility-sparing surgery (compared with standard surgery) and life expectancy varies by tumor size among patients with cervical cancers measuring ≤4 cm in largest diameter. Our secondary objective was to quantify the probability of undergoing adjuvant radiotherapy among patients who underwent fertility-sparing surgery as a function of tumor size. STUDY DESIGN: We identified patients in the National Cancer Database aged ≤45 years, diagnosed with stage I cervical cancer with tumors ≤4 cm between 2006 and 2018, who received no preoperative radiation or chemotherapy, and who underwent either fertility-sparing surgery (cone or trachelectomy, either simple or radical) or standard surgery (simple or radical hysterectomy) as their primary treatment. Propensity-score matching was performed to compare patients who underwent fertility-sparing surgery with those who underwent standard surgery. A flexible parametric model was employed to quantify the difference in life expectancy within 5 years of diagnosis (restricted mean survival time) based on tumor size among patients who underwent fertility-sparing and those who underwent standard surgery. In addition, among those who underwent fertility-sparing surgery, a logistic regression model was used to explore the relationship between tumor size and the probability of receiving adjuvant radiation. RESULTS: A total of 11,946 patients met the inclusion criteria of whom 904 (7.6%) underwent fertility-sparing surgery. After propensity-score matching, 897 patients who underwent fertility-sparing surgery were matched 1:1 with those who underwent standard surgery. Although the 5-year life expectancy was similar among patients who had fertility sparing surgery and those who had standard surgery regardless of tumor sizes, the estimates of life-expectancy differences associated with fertility-sparing surgery were more precise among patients with smaller tumors (1-cm tumor: restricted mean survival time difference, -0.10 months; 95% confidence interval, -0.67 to 0.47) than among those with larger tumors (4-cm tumor: restricted mean survival time difference, -0.11 months; 95% confidence interval, -3.79 to 3.57). The probability of receiving adjuvant radiation increased with tumor size, ranging from 5.6% (95% confidence interval, 3.9-7.9) for a 1-cm tumor to 37% (95% confidence interval, 24.3-51.8) for a 4-cm tumor. CONCLUSION: Within 5 years of diagnosis, young patients with stage I cancers measuring ≤4 cm had similar survival outcomes after either fertility-sparing surgery or standard surgery. However, because few patients with tumors >2 cm underwent fertility-sparing surgery, a clinically important survival difference could not be excluded in this population.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Jorgensen KA, Agusti N, Wu CF, et al. Fertility-sparing surgery vs standard surgery for early-stage cervical cancer: difference in 5-year life expectancy by tumor size. Am J Obstet Gynecol. 2024. PMID: 38365097. doi:10.1016/j.ajog.2024.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。